- Home
- WBS vs ROIV Comparison
WBS vs ROIV Comparison
Compare WBS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBS
- ROIV
- Stock Information
- Founded
- WBS 1935
- ROIV 2014
- Country
- WBS United States
- ROIV United Kingdom
- Employees
- WBS N/A
- ROIV N/A
- Industry
- WBS Major Banks
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- WBS Finance
- ROIV Health Care
- Exchange
- WBS Nasdaq
- ROIV Nasdaq
- Market Cap
- WBS 9.7B
- ROIV 8.6B
- IPO Year
- WBS N/A
- ROIV N/A
- Fundamental
- Price
- WBS $59.48
- ROIV $14.18
- Analyst Decision
- WBS Buy
- ROIV Strong Buy
- Analyst Count
- WBS 15
- ROIV 4
- Target Price
- WBS $68.07
- ROIV $15.50
- AVG Volume (30 Days)
- WBS 1.2M
- ROIV 6.8M
- Earning Date
- WBS 10-16-2025
- ROIV 11-11-2025
- Dividend Yield
- WBS 2.70%
- ROIV N/A
- EPS Growth
- WBS 6.88
- ROIV N/A
- EPS
- WBS 4.92
- ROIV N/A
- Revenue
- WBS $2,486,236,000.00
- ROIV $23,233,000.00
- Revenue This Year
- WBS $7.07
- ROIV N/A
- Revenue Next Year
- WBS $4.85
- ROIV $281.14
- P/E Ratio
- WBS $12.04
- ROIV N/A
- Revenue Growth
- WBS 2.60
- ROIV N/A
- 52 Week Low
- WBS $39.43
- ROIV $8.73
- 52 Week High
- WBS $63.99
- ROIV $14.48
- Technical
- Relative Strength Index (RSI)
- WBS 44.65
- ROIV 75.19
- Support Level
- WBS $61.14
- ROIV $13.81
- Resistance Level
- WBS $62.06
- ROIV $14.48
- Average True Range (ATR)
- WBS 1.28
- ROIV 0.43
- MACD
- WBS -0.34
- ROIV 0.17
- Stochastic Oscillator
- WBS 14.18
- ROIV 88.76
About WBS Webster Financial Corporation
Webster Financial Corp is a full-service provider of financial services, offering commercial and consumer banking, mortgages, and investment advisory along with trust and wealth management services in Connecticut, New York, Rhode Island, Massachusetts, and Pennsylvania. The company's segment includes Commercial Banking, HSA Bank, and Consumer Banking. It generates maximum revenue from the Commercial Banking segment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.